Document is current

Article History

Accepted: 16 March 2025

First Online: 16 April 2025

Declarations

:

: This work was supported by ReCor Medical.

: R.S.T. has received personal consultancy fees from ReCor Medical. A.C. has received personal consultancy fees from ReCor Medical. S.B. has no personal disclosures and support to her department by ReCor. J.D. has no disclosures to declare. S.C. is an employee of ReCor Medical. K.M. is an employee of ReCor Medical. M-C.M. is share-holder and the CEO of Centre Européen de Recherche Cardiovasculaire (CERC), contractor for ReCoR Medical. I-D.Z. has received grant support and nonfinancial support from CERC related to this work and not personally related to this work. I-D.Z. is editorial board member of PharmacoEconomics Open. I-D.Z. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. L.N. is an employee of the Centre Européen de Recherche Cardiovasculaire (CERC), contractor for ReCoR Medical. M.A. has received grants from the European Horizon 2020 program and AstraZeneca; grants and nonfinancial support from Recor Medical, Idorsia, and Novartis; and personal fees from Alnylam Pharmaceuticals, Cincor, Medtronic, Servier, AstraZeneca, and Novartis. A.J.K. reports Institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Siemens, Philips, ReCor Medical, Neurotronic. In addition to research grants, institutional funding includes fees paid to Columbia University and/or the Cardiovascular Research Foundation for consulting and/or speaking engagements in which A.J.K. controlled the content. Personal: Consulting from IMDS; M.A. has received research grants from the French Ministry of Health, Quantum Genomics and the European Horizon 2020 program; has received grant support and nonfinancial support from ReCor Medical and Idorsia; and has received personal fees from CVRx.

: The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

: Not applicable.

: Not applicable.

: Not applicable.

: The cost-effectiveness model was developed in Microsoft Excel 365 (Microsoft Corporation, Redmond, WA, USA). Any additional information about model programming is available from the corresponding author upon request.

: The economic model was updated by K.M. and R.S.T., and K.M. wrote the first draft of this manuscript. All authors revised and contributed to subsequent versions of the manuscript, and the final version was approved by all authors.